Just MS News, June 22 - 28: Remyelination Trial, SPMS Approval, Fatigue, Cognition, and Balance

This week on Just MS News, we reviewed 139 MS-related articles from June 22–28, 2026, and narrowed them down to the stories most worth your time.

The lead story this week is early, but meaningful: PTD802, an oral remyelination therapy, has been cleared for its first human trial. It is not an approved treatment, and it is not a cure. But for people living with MS, research focused on myelin repair is worth paying attention to.

We also cover Sanofi’s Cenrifki, also known as tolebrutinib, being approved in Europe for adults with non-relapsing secondary progressive MS. This is one of the biggest confirmed treatment stories of the week, especially for progressive MS, but it also comes with important safety monitoring.

Other stories this week include blood-based NfL testing for MS monitoring, early high-efficacy treatment in childhood-onset MS, light therapy glasses for MS-related fatigue, menopause and cognition, balance training, cognitive coaching, ocrelizumab and rituximab infection-risk research, vision recovery research, and a human story from the National MS Society called “From Patient to Researcher: How MS Changed My Path.”

As always, this is not medical advice. Just MS News is a calm weekly recap meant to help people living with MS, caregivers, advocates, and supporters understand what is happening in MS news without the overload.

Main Story Links

1. PTD802 oral remyelination therapy
   https://www.neurologylive.com/view/fda-clears-investigational-new-drug-application-remyelinating-agent-ptd802-multiple-sclerosis
2. Cenrifki approved in Europe for non-relapsing SPMS
   https://pmlive.com/sanofis-cenrifki-approved-in-europe-for-secondary-progressive-ms-without-relapses/
3. Blood-based NfL testing and MS monitoring
   https://www.technologynetworks.com/tn/blog/how-blood-based-nfl-testing-could-transform-multiple-sclerosis-management-414010
4. Early high-efficacy treatment in children with MS
   https://www.msaustralia.org.au/news/early-treatment-with-highly-effective-therapy-could-reduce-long-term-disability-in-children-with-ms/
5. Light therapy glasses for MS fatigue
   https://www.nature.com/articles/s41598-026-56950-3
6. Menopause and MS cognition
   https://www.neurologyadvisor.com/features/menopause-and-multiple-sclerosis-neurologic-manifestations/
7. Balance training for MS
   https://clinician.nejm.org/balance-training-multiple-sclerosis-nejm-jw.NA46017
8. Mindset coaching for MS cognitive symptoms
   https://multiplesclerosisnewstoday.com/news-posts/2026/06/22/trial-target-ms-cognitive-symptoms-mindset-coaching/
9. Ocrelizumab and rituximab serious infection risk
   https://verahealth.ai/fr/news/multiple-sclerosis-ocrelizumab-and-rituximab-show-similar-serious-infection-risk
10. Vision recovery research
    https://iovs.arvojournals.org/article.aspx?articleid=2814516
11. From Patient to Researcher: How MS Changed My Path
    https://www.nationalmssociety.org/news-and-magazine/momentum-magazine/from-the-community/from-patient-to-researcher-ms-changed-my-path

The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.

www.justmultiplesclerosis.com